Stage and histological grade of gastrointestinal stromal tumors based on a new approach are strongly associated with clinical behaviors

Modern Pathology

Volumn 22, Issue 4, 2009, Pages 556-569

  Hou, Ying Yong ^a   Lu, Shao Hua ^a   Zhou, Yang ^a   Qi, Wei Dong ^a   Shi, Yuan ^a   Tan, Yun Shan ^a   Zhu, Xiong Zeng ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Disease free survival; Gastrointestinal stromal tumor; Grade; Overall survival; Stage

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS;

EID: 63949087432     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.11     Document Type: Article

References (59)

1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
2. Hirota 8, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-667.
3. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
4. Chen LL, Trout JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64:5913-5919.
5. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620-625.
6. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-632.
7. Salazar M, Barata A, Andre S, et al. First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy. Gut 2006;55:585-586.
8. Haller F, Detken S, Schulten HJ, et al. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Ann Surg Oncol 2007;14:526-532.
9. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14-24.
10. Akwari OE, Dozois RR, Weiland LH, et al. Leiomyosarcoma of the small and large bowel. Cancer 1978;42:1375-1384.
11. Shiu MH, Farr GH, Papachristou DN, et al. Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 1982;49:177-187.
12. McGrath PC, Neifeld JP, Lawrence Jr W, et al. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 1987;206:706-710.
13. Hasegawa T, Matsuno Y, Shimoda T, et al. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669-676.
14. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898-3905.
15. Shirin H, Kravtsov V, Shahmurov M, et al. The cyclindependent kinase inhibitor, p27, has no correlation with the malignant potential of GIST. Digestion 2007;75:4-9.
16. Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992;215:68-77.
17. Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 1995;2:26-31.
18. Gutierrez JC, Dc Oliveira LO, Perez EA, et al. Optimizing diagnosis, staging, and management of gastrointestinal stromal tumors. J Am Coil Surg 2007;205:479-491.
19. Hou YZX, Lu S, Zhou Y, et al. Study on malignancy, staging and grading for gastrointestinal stromal tumors. The 44th ASCO Annual Meeting. Chicago, 2008.
20. Trupiano JK, Stewart RE, Misick C, et al. Gastric stromal tumors: a clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors. J Am Surg Pathol 2002; 26:705-714.
21. Yan H, Marchettini P, Acherman YI, et al. Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 2003;26:221-228.
22. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68.
23. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477-489.
24. Miettinen M, Sarlomo-Rikala M, Sobin LH, et al. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000;24:211-222.
25. Koga H, Ochiai A, Nakanishi Y, et al. Reevaluation of prognostic factors in gastric leiomyosarcoma. Am J Gastroenterol 1995;90:1307-1312.
26. Fujimoto Y, Nakanishi Y, Yoshimura K, et al. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003;6:39-48.
27. Tworek JA, Goldblum JR, Weiss SW, et al. Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases. Am J Surg Pathol 1999;23:937-945.
28. Tworek JA, Goldblum JR, Weiss SW, et al. Stromal tumors of the anorectum: a clinicopathologic study of 22 cases. Am J Surg Pathol 1999;23:946-954.
29. Miettinen M, Sarlomo-Rikala M, Sobin LH, et al. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000;24:1339-1352.
30. Miettinen M, Furlong M, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001;25:1121-1133
31. Cooper PN, Quirke P, Hardy GJ, et al. A flow cytometric, clinical, and histological study of stromal neoplasms of the gastrointestinal tract. Am J Surg Pathol 1992;16:163-170.
32. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
33. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-1220.
34. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-4774.
35. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127:294-299.
36. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-4190.
37. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-896.
38. Andersson J, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006;130:1573-1581.
39. Ernst SI, Hubbs AE, Przygodzki RM, et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998;78:1633-1636.
40. Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53-60.
41. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GElS). J Clin Oncol 2005;23:6190-6198.
42. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297-4300.
43. Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003;106:887-895.
44. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121.
45. Lasota J, Kopczynski J, Sarlomo-Rikala M, et al. KIT lS3Oins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 2003;34:1306-1312.
46. Lasota J, Dansonka-Mieszkowska A, Stachura T, et al. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 2003;16:1257-1264.
47. Lasota J, Dansonka-Mieszkowska A, Sobin LH, et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004;84:874-883.
48. Lasota J, vol Dobosz AJ, Wasag B, et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest 2007;87:1029-1041.
49. Bruck R, Arber N. Prognostic markers in gastrointestinal stromal tumors-we are not there yet. Digestion 2007;75:1-3.
50. Kimura H, Yonemura Y, Kadoya N, et al. Prognostic factors in primary gastrointestinal leiomyosarcoma: a retrospective study. World J Surg 1991;15:771-776.
51. Ueyama T, Guo KJ, Hashimoto H, et al. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992;69:947-955.
52. Tazawa K, Tsukada K, Makuuchi H, et al. An immunohistochemical and clinicopathological study of gastrointestinal stromal tumors. Pathol Int 1999;49:786-798.
53. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51-58.
54. Evans HL. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 1985;56:2242-2250.
55. Franquemont DW, Frierson Jr HF. Muscle differentiation and clinicopathologin features of gastrointestinal stromal tumors. Am J Surg Pathol 1992;16:947-954.
56. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-1478.
57. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83.
58. Huang HY, Li CF, Huang WW, et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome, Surgery 2007;141:748-756.
59. Deyrup AT, Weiss SW. Grading of soft tissue sarcomas: the challenge of providing precise information in an imprecise world. Histopathology 2006;48:42-50.